Tresiba Cost in Wyoming 2026: What You'll Actually Pay for Insulin Degludec

What Does Tresiba Cost Without Insurance in Wyoming?

Tresiba's manufacturer list price sits near $510 per month, but Wyoming patients paying cash rarely pay that amount. Across Wyoming retail pharmacies in 2026, the average cash-pay price lands around $35 per month after GoodRx-style discount coupons and pharmacy-specific pricing agreements are applied. That gap between $510 and $35 is not a rounding error. It reflects the spread between the wholesale acquisition cost that Novo Nordisk sets and the negotiated contract rates that large pharmacy benefit networks pass on to coupon users.

Insulin degludec is a long-acting basal insulin with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, which distinguishes it pharmacokinetically from insulin glargine U-300 and detemir [1]. The DEVOTE trial (N=7,637) compared insulin degludec to insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk and found that degludec was non-inferior for major adverse cardiovascular events (MACE) while producing a 40% lower rate of severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48-0.76, P<0.001 for superiority) [2]. That hypoglycemia advantage is one reason clinicians at HealthRX often consider insulin degludec over older basal insulins for patients who report nocturnal lows.

List price does not equal patient cost. At the pharmacy counter in Wyoming, what you pay depends on whether you have commercial insurance, Medicaid, Medicare Part D, or no coverage at all. Each pathway carries a different price floor and a different set of access barriers.

Before visiting any pharmacy, request a price check using your GoodRx or RxSaver code. Wyoming has no state-specific insulin pricing cap as of 2026, unlike states such as Colorado, which legislated a $35/month cap for commercially insured patients [3]. Wyoming patients without insurance rely on manufacturer programs and pharmacy discount tools entirely.

Does Wyoming Medicaid Cover Tresiba?

Wyoming Medicaid does not cover Tresiba as of 2026. The Wyoming Department of Health's Medicaid preferred drug list places long-acting insulin coverage on biosimilar and older branded products; insulin degludec (Tresiba) is not on the preferred list and prior authorization approval is rarely granted [4]. Patients enrolled in Wyoming Medicaid who require a long-acting basal insulin are typically directed to insulin glargine biosimilars such as Semglee or Basaglar, both of which carry preferred status.

"Formulary placement for basal insulins on state Medicaid programs has lagged behind clinical evidence in many states," according to a 2023 analysis published in Diabetes Care examining Medicaid insulin access barriers nationally [5]. Wyoming's exclusion of degludec is consistent with that pattern.

If a Wyoming Medicaid prescriber believes insulin degludec is medically necessary, a prior authorization request citing the DEVOTE trial's hypoglycemia data [2] and documenting failure or contraindication of preferred agents represents the strongest clinical argument. Approval rates for such requests in Wyoming are not publicly reported, but nationally fewer than 20% of insulin prior authorizations for non-preferred agents succeed on first submission [6].

Patients who cannot obtain Medicaid coverage for Tresiba have three realistic alternatives: switch to a Medicaid-covered basal insulin, pursue the Novo Nordisk Patient Assistance Program (PAP) for free branded Tresiba, or explore 503A-compounded insulin degludec through a licensed Wyoming pharmacy or one that ships to Wyoming.

How Does Wyoming Medicare Part D Cover Tresiba?

Medicare Part D formulary placement for Tresiba varies by plan. As of 2026, several Part D plans operating in Wyoming place insulin degludec on Tier 3 or Tier 4, resulting in copays that range from approximately $35 to $95 per month during the deductible phase under the Inflation Reduction Act's $35/month insulin copay cap for Medicare beneficiaries [7]. The Inflation Reduction Act cap applies to all covered insulins on a Part D formulary; if Tresiba is on your plan's formulary at any tier, your monthly cost cannot exceed $35.

Wyoming Part D enrollees should confirm Tresiba's formulary status through Medicare Plan Finder at medicare.gov before each annual enrollment period. If your current plan does not list insulin degludec, switching during open enrollment to one that does is straightforward and can reduce cost to $35/month immediately on January 1.

Patients with Medicare who also carry a Medigap or Medicare Advantage policy should check whether those plans impose additional insulin cost-sharing beyond the Part D floor. Some Medicare Advantage plans build in zero copay for preferred insulins, which may or may not include degludec depending on the plan's pharmacy benefit manager contract.

Which Commercial Insurance Plans Cover Tresiba in Wyoming?

Wyoming's commercial insurance market is thin. The largest employer-sponsored and ACA marketplace plans operating in the state include BlueCross BlueShield of Wyoming, Cigna, and UnitedHealthcare. Tresiba's formulary placement differs across these carriers.

BlueCross BlueShield of Wyoming and most UnitedHealthcare commercial plans in the state typically place Tresiba on Tier 3 or Tier 4, requiring a prior authorization in many cases. Cigna commercial plans have historically placed insulin degludec on Tier 3 with PA requirements tied to trial of a preferred basal insulin [8]. Tier 3 copays in Wyoming employer plans average $60-$90 per 30-day supply before deductible and $30-$60 after deductible, though exact figures depend on the employer's benefit design.

For commercially insured patients, the Novo Nordisk My$99Insulin program caps out-of-pocket cost at $99 per month regardless of insurance tier, and the branded savings card program may reduce that further. See the Novo Nordisk savings section below for specifics.

Prior authorization approval is more common with commercial insurers than with Medicaid if the prescriber documents a hypoglycemia history, A1C failure on glargine, or a clinical reason such as variable injection timing that makes degludec's longer duration of action clinically relevant. The FDA label for Tresiba notes the flexibility of dose timing, stating that the dose can be administered at any time of day and does not need to be given at the same time each day [1].

Is Compounded Insulin Degludec Legal in Wyoming?

Compounded insulin degludec is legally available to Wyoming patients through 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific compounded medications when a valid prescription is present [9]. Wyoming's Board of Pharmacy licenses 503A pharmacies under rules consistent with federal law, and compounded insulin degludec is not currently on the FDA's list of drugs that may not be compounded under 503A.

This is a meaningful access point. Qualifying patients who obtain a prescription from a licensed prescriber, whether in-person or via telehealth, may receive compounded insulin degludec at dramatically reduced cost. Some 503A pharmacies that ship to Wyoming offer compounded insulin degludec at effectively $0 per month through provider-sponsored access programs, though patients should verify each pharmacy's licensure with the Wyoming Board of Pharmacy before filling [10].

The regulatory distinction between 503A (patient-specific, prescription-required, no large-scale distribution) and 503B (outsourcing facilities, larger scale, no individual prescription required) matters here. Insulin degludec compounded under 503A is legal in Wyoming. Compounded insulin degludec from a 503B outsourcing facility would face additional FDA restrictions. Patients and prescribers should confirm which category their compounding pharmacy operates under.

Compounded insulin degludec is not FDA-approved and is not therapeutically rated as bioequivalent to branded Tresiba. Clinical substitution decisions require physician oversight. A 2022 review in the American Journal of Health-System Pharmacy noted that compounded insulins may differ in concentration, excipient composition, and sterility standards compared to manufacturer-produced products [11].

Can You Get a Tresiba Prescription via Telehealth in Wyoming?

Telehealth prescribing of Tresiba is legal in Wyoming. Wyoming adopted permanent telehealth prescribing rules post-pandemic that allow controlled and non-controlled medications to be prescribed following a valid patient-provider relationship established via synchronous audio-visual telehealth visit [12]. Insulin degludec is not a controlled substance, so no DEA-specific restrictions apply.

HealthRX providers licensed in Wyoming can evaluate patients for basal insulin therapy, assess A1C, review CGM data, and prescribe Tresiba or compounded insulin degludec during a single telehealth visit. Wyoming's low population density, with 580,000 residents spread across 97,914 square miles, means that telehealth is not simply a convenience in this state. For many Wyoming patients, it is the primary access point for endocrinology-level diabetes management.

After a telehealth visit, the prescription can be sent to a local Wyoming pharmacy or to a mail-order or 503A compounding pharmacy depending on which access pathway the patient and provider select. Telehealth does not reduce pharmacy cost directly, but it enables access to savings programs and compounding options that a patient might not reach without a current, active prescription.

What Is the Novo Nordisk Savings Card and How Does It Work in Wyoming?

Novo Nordisk offers two distinct patient affordability programs for Tresiba that Wyoming residents can access.

The first is the My$99Insulin program, which caps cost at $99 per month for commercially insured patients regardless of insurance tier or prior authorization status. Patients present a savings card at the pharmacy alongside their insurance card, and Novo Nordisk covers the difference between the $99 patient share and the insurance adjudicated cost. Uninsured patients may also qualify for a $99 cash price through this program. Enrollment is available at the Novo Nordisk patient assistance site and takes approximately 10-15 minutes [13].

The second program is the Novo Nordisk Patient Assistance Program (PAP), which provides Tresiba at no cost to patients who meet income thresholds, typically at or below 400% of the federal poverty level with no other insulin coverage. A Wyoming household of one person earning under approximately $58,000 per year in 2026 may qualify. Prescribers submit PAP applications on the patient's behalf, and approved patients receive 90-day supplies shipped directly from Novo Nordisk [13].

Neither program is available to Medicare or Medicaid beneficiaries, per federal anti-kickback statute restrictions. Wyoming Medicaid and Medicare Part D patients must use the routes described in earlier sections.

What Is the Cheapest Way to Get Tresiba in Wyoming in 2026?

The answer depends on your insurance status.

For commercially insured Wyoming patients, the Novo Nordisk $99 savings card combined with insurance billing typically results in the lowest cost, often $35-$99 per month.

For Wyoming Medicaid patients, Tresiba is not covered, and the PAP program (free branded Tresiba for income-qualifying patients) or 503A compounded insulin degludec (potentially $0/month) represent the lowest-cost options.

For Medicare Part D enrollees with Tresiba on their formulary, the Inflation Reduction Act $35/month cap applies directly [7]. No additional savings card is needed or permitted under Medicare.

For uninsured Wyoming patients, GoodRx-type discount codes at retail pharmacies reduce Tresiba to approximately $35/month. The My$99Insulin program from Novo Nordisk may offer comparable pricing without requiring a GoodRx coupon. Compounded insulin degludec via a 503A pharmacy, if clinically appropriate and prescribed by a licensed provider, may be the lowest-cost option of all.

Cost-effectiveness modeling published in Diabetes Care comparing insulin degludec to glargine U-100 estimated that degludec's lower hypoglycemia rate could offset some of its higher acquisition cost at a threshold of approximately $150,000 per quality-adjusted life year (QALY) gained, though this analysis used U.S. list prices rather than the discounted prices available to most Wyoming patients [14]. At $35/month cash pay, the cost-effectiveness picture changes substantially.

Clinical Profile of Insulin Degludec: What Wyoming Prescribers Should Know

Insulin degludec (Tresiba) received FDA approval in September 2015 for adults and pediatric patients aged 1 year and older with type 1 or type 2 diabetes [1]. It is available as a U-100 and U-200 formulation. The U-200 formulation delivers twice the insulin concentration per unit volume, which is useful for patients requiring large doses and seeking to reduce injection volume.

The pharmacokinetic profile of degludec differs meaningfully from other basal insulins. After subcutaneous injection, insulin degludec forms multi-hexameric complexes at the injection site, creating a depot that releases monomers slowly into circulation [1]. This mechanism produces an ultra-long duration of action (more than 42 hours) with a flat, peakless pharmacodynamic profile as confirmed by euglycemic clamp studies [15]. The result is a lower intra-patient variability coefficient compared to insulin glargine U-100, a property with direct relevance to nocturnal hypoglycemia risk.

The DEVOTE trial, published in the New England Journal of Medicine in 2017, remains the landmark cardiovascular outcomes trial for insulin degludec. In 7,637 patients with type 2 diabetes and high cardiovascular risk followed for a median of 2.0 years, degludec was non-inferior to glargine U-100 for three-point MACE (HR 0.91 to 95% CI 0.78-1.06) [2]. Severe hypoglycemia occurred in 4.9% of degludec-treated patients versus 6.6% of glargine-treated patients, a statistically significant superiority finding with P<0.001 [2].

A 2021 meta-analysis in The Lancet Diabetes and Endocrinology pooling data from eight randomized trials (N=10,415) found that insulin degludec reduced the rate of nocturnal confirmed hypoglycemia by 25-36% relative to insulin glargine across both type 1 and type 2 diabetes populations [16]. For Wyoming patients with unpredictable meal schedules, limited access to endocrinology follow-up, or a history of hypoglycemia unawareness, that profile is clinically meaningful.

The American Diabetes Association 2024 Standards of Care note that for patients with recurrent symptomatic or nocturnal hypoglycemia, switching from NPH or glargine U-100 to degludec or glargine U-300 is a reasonable strategy [17]. Wyoming prescribers using telehealth platforms can apply this guidance when selecting between covered and non-covered basal insulin options for their patients.

Starting dose for insulin-naive type 2 diabetes patients is typically 10 units subcutaneously once daily, adjusted by 2 units every 3 days based on fasting glucose targets [1]. For patients transferring from another basal insulin on a unit-to-unit basis, dose adjustments in the first 1-2 weeks are common due to degludec's longer duration of action.

Are There Wyoming-Specific Diabetes Resources for Tresiba Patients?

Wyoming does not have a state-run insulin assistance program beyond Medicaid. The Wyoming Department of Health Diabetes Prevention Program coordinates with the CDC's National Diabetes Prevention Program but does not provide drug access support [18]. Wyoming's four Federally Qualified Health Centers (FQHCs) can access 340B drug pricing, which in some cases allows them to dispense Tresiba to qualifying low-income patients at substantially reduced cost. Patients should ask their FQHC provider whether the facility participates in 340B and whether Tresiba is available through that channel.

The American Diabetes Association's Diabetes Advocacy page maintains a state-by-state insulin access tool that Wyoming residents can use to check current program availability [17]. Insulin Help, a non-profit that operates nationally, also maintains a resource directory that includes Wyoming-accessible programs and is updated quarterly.